HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients-Reference-Cited by-同舟云学术

HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients

Published:2022-11 Issue:2 Volume:167 Page:234-238
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Menzies Anya V.,Usher Erik C.,Hsu Fang-Chi,Levine Edward A.,Lentz Samuel S.,Kelly Michael G.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference24 articles.

1. Cancer of the ovary;Cannistra;N. Engl. J. Med.,2004

2. Ovarian cancer: a brief historical overview of intraperitoneal trials;Kwa;Ann. Surg. Oncol.,2014

3. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study [published correction appears in J Clin Oncol. 2019 Sep 1;37(25):2299];Walker;J. Clin. Oncol.,2019

4. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N. Engl. J. Med.,2006

5. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution;Elias;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./ ESMO.,2002

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hyperthermic intraperitoneal chemotherapy (HIPEC) vs. postoperative intraperitoneal (IP) chemotherapy – Impact on health-related quality of life in primary ovarian cancer patients after cytoreductive surgery;Surgical Oncology Insight;2024-09

2. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer;Current Oncology;2023-12-01